Intercept Pharmaceuticals (NASDAQ: ICPT) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Intercept Pharmaceuticals to related companies based on the strength of its institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.
This is a summary of current ratings for Intercept Pharmaceuticals and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Intercept Pharmaceuticals Competitors||1133||3423||11925||240||2.67|
Intercept Pharmaceuticals currently has a consensus target price of $140.45, indicating a potential upside of 155.60%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 38.78%. Given Intercept Pharmaceuticals’ higher probable upside, analysts clearly believe Intercept Pharmaceuticals is more favorable than its competitors.
Valuation and Earnings
This table compares Intercept Pharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Intercept Pharmaceuticals||$24.95 million||-$412.83 million||-3.71|
|Intercept Pharmaceuticals Competitors||$290.27 million||$35.99 million||58.52|
Intercept Pharmaceuticals’ competitors have higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Intercept Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Intercept Pharmaceuticals Competitors||-6,123.02%||-161.27%||-36.09%|
Volatility & Risk
Intercept Pharmaceuticals has a beta of -2.05, suggesting that its stock price is 305% less volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals’ competitors have a beta of 5.81, suggesting that their average stock price is 481% more volatile than the S&P 500.
Insider and Institutional Ownership
73.8% of Intercept Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 9.2% of Intercept Pharmaceuticals shares are held by insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Intercept Pharmaceuticals competitors beat Intercept Pharmaceuticals on 10 of the 13 factors compared.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company’s product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.